parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in adrenal cortex cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 234	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 12927

TBC1D4 in dopamine neurons, braak-0.19 (p 0.630) → +0.41 (p 0.277)receipt 12934
TBC1D4 in microglia, braak+0.21 (p 0.586) → -0.55 (p 0.122)receipt 12933

receipt 12934: TBC1D4 in dopamine neurons, braak

power: full sample +0.13 (p 0.621, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.13 (p 0.621, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.728, n 18). could be the mix.
skeptic: leave-one-out range -0.01 to +0.23, sign flips 1; without severely affected donors +0.13 (p 0.621, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TBC1D4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12933: TBC1D4 in microglia, braak

power: full sample -0.15 (p 0.555, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.28 (p 0.254, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.24 (p 0.346, n 18). could be the mix.
skeptic: leave-one-out range -0.26 to -0.03, sign flips 0; without severely affected donors -0.15 (p 0.555, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TBC1D4 in microglia.

case closed: nothing better to follow up.

loading the receipts